Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0085580 (essential hypertension)
 14,686 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Aldosterone synthase is a mitochondrial enzyme that catalyzes the conversion of 11-deoxycorticosterone to the potent mineralocorticoid aldosterone. The gene encoding aldosterone synthase, CYP11B2, is associated with essential hypertension. But if the genetic variations in aldosterone synthesis could influence the antihypertensive response to Valsartan is not clear. A Chinese sample of 502 persons (217 women) was studied, which was divided into the hypertensive group (EH) of 345 persons and the normotensive group (NB) of 157 persons. Subjects were genotyped through the use of the polymerase chain reaction for the diallelic polymorphisms in CYP11B2. 98 persons of the essential hypertension group received 4 weeks therapy with valsartan. Blood pressure, 24-hour ambulatory blood pressure, biochemical index were also determined. The frequency of CC+CT genotypes in hypertensive group was significantly higher than that in normotensive group (P<0.05), the frequency of C allele of gene CYP11B2 (-344T/C) in hypertensive group was significantly higher than that in normotensive group (P<0.01). The descending values of SBP (systolic blood pressure), DBP (diastolic blood pressure), MAP (mean arterial pressure), 24 h SBP (mean SBP of 24 hours), 24 h DBP (mean DBP of 24 hours), 24 h MAP (mean arterial pressure of 24 hours) of CC+CT genotype group were significantly higher than those of the TT genotype group (P<0.05). The aldosterone synthase CYP11B2 (-344T/C) gene polymorphism is associated with essential hypertension in Chinese. And the aldosterone synthase CYP11B2 (-344T/C) gene polymorphism may be the predictor of the antihypertensive response to Valsartan.
...
PMID:Associations between human aldosterone synthase CYP11B2 (-344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension. 2578 10

Twelve males with moderately severe essential hypertension (mean arterial pressure [MAP] ranging 113-162 mmHg) were studied at rest supine and sitting and during bicycle exercise (50, 100 and 150 W). Intraarterial blood pressure (BP), and heart rate (HR) were recorded continuously. Cardiac output (CO) was measured by dye dilution (Cardiogreen). After 6-8 months (enalapril dose 10-40 mg daily) patients were restudied. BP fell in all patients, at rest sitting from 184/107 mmHg to 150/87 (-19%) and during 100 W from 223/117 to 194/98 mmHg (p < 0.001). Pretreatment total peripheral resistance index (TPRI) was greatly increased in all patients and fell from 4137 to 3651 dyn s cm-5 m2 (-16%) (p < 0.05). No significant changes were seen in CO, HR or stroke volume. No side effects were seen. It is concluded that enalapril reduces BP in patients with moderately severe hypertension at rest and during exercise due to reduction in TPRI without significant changes in CO or HR.
 ...
PMID:Long-Term Haemodynamic Effects of Enalapril at Rest and During Exercise in Essential Hypertension. 2778 9


<< Previous 1 2 3 4 5